K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer

European Journal of Surgical Oncology

Volumn 36, Issue 7, 2010, Pages 657-662

  Chen, H ^a   Tu, H ^b   Meng, Z Q ^a   Chen, Z ^a   Wang, P ^a   Liu, L M ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

K ras gene; Prognostic factors; Survival; Unresectable pancreatic cancer

Indexed keywords

DNA; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE MUTATION; HAZARD RATIO; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SURVIVAL TIME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CODON; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77953916705     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.05.014     Document Type: Article

References (30)

1. Simon B., and Printz H. Epidemiological trends in pancreatic neoplasias. Dig Dis 19 1 (2001) 6-14
2. Castells A., Puig P., Mora J., et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 17 2 (1999) 578-584
3. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 18 (2004) 3776-3783
4. Michaud D.S., Giovannucci E., Willett W.C., et al. Physical activity, obesity, height, and the risk of pancreatic cancer. J Am Med Assoc 286 8 (2001) 92-99
5. Iodice S., Gandini S., Maisonneuve P., et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393 4 (2008) 535-545
6. Krishnan S., Rana V., Janjan N.A., et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107 11 (2006) 2589-2596
7. Engelken F.J., Bettschart V., Rahman M.Q., et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29 4 (2003) 368-373
8. Koom W.S., Seong J., Kim Y.B., et al. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 73 4 (2009) 1148-1154
9. Murphy N.C., Scarlett C.J., Kench J.G., et al. Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. Br J Cancer 98 3 (2008) 537-541
10. Wang P., Fan J., Chen Z., et al. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol 16 4 (2009) 826-835
11. Jiao L., Zhu J., Hassan M.M., et al. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients in relation to cigarette smoking. Pancreas 34 1 (2007) 55-62
12. Nakata K., Ohuchida K., Naqai E., et al. Lmo2 is a novel predictive marker of a better prognois in pancrestic cancer. Neoplasia 11 7 (2009) 712-719
13. Maire F., Micard S., Hammel P., et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 87 5 (2002) 551-554
14. Däbritz J., Preston R.o., Hanfler J., et al. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer correlation with clinical features and carbohydrate antigen 19-9. Pancreas 38 5 (2009) 534-541
15. Wang M., Block T.M., Steel L., et al. Preferential isolation of fragmented DNA enhances the detection of circulating mutated K-ras DNA. Clin Chem 50 1 (2004) 211-213
16. Mora J., Urgell E., Farré A., et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem 52 7 (2006) 1448-1449
17. Leon S.A., Shapiro B., Sklaroff D.M., et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37 3 (1977) 646-650
18. Uemura T., Hibi K., Kaneko T., et al. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 39 1 (2004) 56-60
19. Olsen C.C., Schefter T.E., Chen H., et al. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol 32 2 (2009) 115-121
20. Salek C., Benesova L., Zavoral M., et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 13 27 (2007) 3714-3720
21. Slebos R.J., Hoppin J.A., Tolbert P.E., et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 9 11 (2000) 1223-1232
22. Mulcahy H.E., Lyautey J., Lederrey C., et al. A prospective study of k-ras mutation in plasma of pancreatic cancer patients. Clin Cancer Res 4 2 (1998) 271-275
23. Hruban R.H., van Mansfeld A.D., Offerhaus G.J., et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143 2 (1993) 545-554
24. Pellegata N.S., Sessa F., Renault B., et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54 6 (1994) 1556-1560
25. Scarpa A., Capelli P., Villaneuva A., et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer 57 2 (1994) 167-171
26. Berrozpe G., Schaeffer J., Peinado M.A., et al. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58 2 (1994) 185-191
27. Yamada T., Nakamori S., Ohzato H., et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 4 6 (1998) 1527-1532
28. Salek C., Minarikova P., Benesova L., et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res 29 5 (2009) 1803-1810
29. Niedergethmann M., Rexin M., Hildenbrand R., et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 26 12 (2002) 1578-1587
30. Kawesha A., Ghaneh P., Andrén-Sandberg A., et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89 6 (2000) 469-474